Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

        FDA Memoranda of Understanding

Academic MOUs Home
          About FDA
          Partnerships: Enhancing Science Through Collaborations With FDA
          FDA Memoranda of Understanding
          Academic MOUsFDA Memoranda of Understanding Academic MOUs
  	
        Share
    Post
    Linkedin

    Email
    PrintMOU No.
			Purpose
			Parties
			FDA Lead Center or
			Office/Contact
			Effective Date
			Expiration
			Date
			Last Revision
			Date225-23-010
			Establishes the FDA-ASA Oncology Educational Fellowship. Both parties share interests in promoting scientific progress through exchange of scientific knowledge in statistical methods for clinical research, oncology education, collaborative learning, and research.
			American Statistical Association (ASA)
			Oncology Center of Excellence (OCE)
			Jennifer Gao M.D. 
			Associate Director for Education 
			10903 New Hampshire Ave, WO 22/2135 
			Silver Spring, MD 20993 Jennifer.gao@fda.hhs.gov 
			240-402-4683
			2023-06-06
			2028-09-30225-23-007
			This MOU establishes the terms for collaboration to promote 
			FDA and MSU’s shared interests, which can be pursued through a variety of programs.
			Michigan State University (MSU)
			CDER
			Padmaja Mummaneni, PhD
			(301) 796-2027
			2023-08-01
			2028-08-01
			2023-08-01225-23-002
			This MOU forms the basis for development of scientific collaborations, outreach and educational initiatives and intellectual partnerships between FDA and University of Pennsylvania, Perelman
			School of Medicine.
			Perelman School of Medicine at the University of Pennsylvania (Penn Med)
			Padmaja Mummaneni, Ph.D.
			Consumer Safety Officer, Regulatory Health Project Manager
			Center for Drug Evaluation and Research (CDER), Office of Translational Sciences, Office of Clinical Pharmacology
			301-796-2027
			2023-05-30
			2028-05-30225-20-001
			Maryland Montgomery County Public Schools, collaboration to foster Scientific Technology Engineering and Math studies and career paths, along with educating youth about the dangers of opioid misuse and prevention of substance abuse.
			Maryland, Montgomery Count Public school system
			CDER
			Chekesha Clingman
			(301) 796-8531
			2020-02-12
			2025-02-12225-93-2001
			IL Inst. Tech., participation in short courses, workshops, & training programs in food safety and technology.
			Illinois Institute of Technology
			CFSAN
			Don Zink
			(240) 402-1693
			1993-09-03
			Indefinite225-02-8001
			Establishes terms of collaboration between FDA and UMD to support shared interest in scientific progress through a variety of programs such as sabbaticals, postdoctoral fellowships, and student internships.
			University of Maryland
			OC
			Eileen Parish
			(301) 796-8522
			2002-09-04
			Indefinite225-03-6000
			Establishes terms of collaboration between FDA and VA Polytechnic Institute to support shared interest in scientific progress through a variety of programs such as sabbaticals, postdoctoral fellowships, and student internships.
			University of Houston
			CDRH
			Michelle Chenault
			(240) 276-3815
			2003-03-29
			Indefinite225-03-8002
			Establishes terms of collaboration between FDA and VA Polytechnic Institute to support shared interest in scientific progress through a variety of programs such as sabbaticals, postdoctoral fellowships, and student internships.
			Virginia Polytechnic Institute
			OC
			Eileen Parish
			(301) 796-8522
			2003-03-13
			Indefinite225-03-8003
			Establishes terms of collaboration between FDA and Howard University to support shared interest in scientific progress affecting human and animal health and medicine through a variety of programs such as sabbaticals, postdoctoral fellowships, and student internships.
			Howard University
			OC
			Eileen Parish
			(301) 796-8522
			2003-05-29
			Indefinite225-05-6000
			To establish terms of collaboration between FDA and BWH to support shared interests and to begin the initiative "The FDA Brigham Elective Program for Residents in the Department of Medicine."
			Brigham and Women's Hospital
			CDRH
			Anindita Saha
			(301) 796-2537
			Mimi Nguyen
			(301) 796-4125
			2006-05-09
			Indefinite225-05-6001
			Establishes collaboration between FDA, Duke University, and Duke University Health System, Inc. in sharing scientific information.
			Duke University and Duke University Health System, Inc.
			CDRH
			Annindita Saha
			(301) 796-2537
			Mimi Nguyen
			301-796-4125
			2006-09-18
			Indefinite225-07-6001
			Establishes the terms for collaborative research between the FDA and Stanford University to promote scientific progress in animal and human medicine. Amended to change POC and termination date.
			Stanford University
			CDRH
			Anindita Saha
			(301-796-2537
			Mimi Nguyen
			301-796-4125
			2012-07-12
			Revised on
			2016-05-11
			Indefinite225-07-8005
			To establish terms of collaboration between FDA and Duke, as a part of FDA's Critical Path Initiative. This MOU will serve as the basis of a Public Private Partnership hosted by Duke to systematically modernize the clinical trial process.
			Duke University
			OC
			Melissa Robb
			(301) 827-1516
			2007-09-22
			Indefinite225-07-8008-1
			To establish collaboration in the areas of advanced scientific training, information exchange and stimulation of cooperative research activities in biotechnology, bioethics, and nanotechnology, particularly with the Institute of NanoBioTechnology.  Replaced MOU #s 225-07-8008 and 225-02-8000.
			John Hopkins University
			OC
			Eileen Parish
			(301) 796-8522
			2015-05-20
			2020-05-20225-07-8405
			Forms the basis for development of scientific collaborations, outreach and educational
			initiatives and intellectual partnerships between FDA and USM.
			University System of Maryland
			Office of the Chief Scientist
			2018-04-02
			Indefinite225-11-0024
			Establishes a collaborative framework between the FDA and the University of Florida through a variety of programs, including collaborative education and research. Term Extension Modification.
			University of Florida
			CDER
			Ryan Chatman
			(301) 796-2106
			2011-09-21
			2021-09-19225-12-0004
			Establishes the collaboration between The United States Food and Drug Administration (FDA) and Thomas Jefferson University to share interests in promoting scientific progress through exchange of scientific capital in Clinical Pharmacology Training and Research Program. Time Extension Amendment
			The Thomas Jefferson University
			CDER
			Ryan Chatman
			(301) 796-2106
			2011-12-09
			2021-12-09225-12-0011
			Forms the basis for the initial relations between FDA and the University of Hawaii, College of Pharmacy for sabbaticals, research and scientific education
			University of Hawaii Hilo, College of Pharmacy
			OMH
			Richardae Araojo
			(301) 796-8000
			2012-03-30
			Indefinite225-12-0012
			Forms the basis for the initial relations between FDA and the University of Hawaii for sabbaticals, research and scientific education.
			University of Hawaii at Manoa, Office of Public Health Studies
			OMH
			Richardae Araojo
			(301) 796-8000
			2012-04-24
			Indefinite225-12-0018
			Establishes the terms between the Food and Drug Administration (FDA) and Stanford University (Stanford) to promote scientific progress through exchange of scientific capital in diverse fields of science that affect human and animal health and medicine.
			Stanford University
			CDER
			Gerald J. Dal Pan, MD, MHS
			301-796-2380
			2012-05-17
			Indefinite225-12-0029
			Forms the basis for the initial relations between FDA and Meharry Medical College (Meharry) for sabbaticals, research and scientific education.
			Meharry Medical College
			OMH
			Richardae Araojo
			(301) 796-8000
			2012-06-21
			Indefinite225-13-002
			This MOU establishes the terms for collaboration to promote shared interests, which can be pursued through a variety of programs including collaborative education and research.
			Harvard T.H. Chan School of Public Health
			CDER
			Scott N. Goldie
			General Health Scientist
			(301) 796-2055
			2018-01-18
			2021-01-18225-13-0025
			Establishes terms of collaboration between FDA and the University of Hamburg for development of scientific collaborations, outreach and educational initiatives, and intellectual partnerships.
			University of Hamburg
			CFSAN
			Eric Brown, PhD
			(240) 402-2020
			2013-09-05
			Indefinite225-14-007
			This Memorandum of Understanding (MOU) states the mutual intention of the parties to seek opportunities for collaboration and to promote shared interests in various science-based academic initiatives, fellowships, and student internships.
			York College of the City University of New York
			OMH
			Richardae Araojo
			(301) 796-8000
			2014-02-20
			Indefinite225-15-006
			Collaboration to promote these shared interests, which can be pursued through information sharing in regulatory science research, training, sabbaticals, postdoctoral fellowships, and student internships.
			Morehouse School of Medicine
			OMH
			Richardae Araojo
			(301) 796-8000
			2014-12-22
			Indefinite225-15-013
			Shared interests in promoting scientific progress through exchange of scientific capital in Clinical Pharmacology Training and Research Programs. This was amended to extend the termination date to June 30, 2021.
			University of California at San Diego
			CDER
			2012-06-30
			Revised on:
			2018-05-08,
			2021-08-06
			2026-08-06225-16-001
			Identify indicators of cardiovascular risk, predict adverse cardiovascular events associated with therapeutic interventions, and improve the clinical utility of biomarker technologies as diagnostic and assessment tools that facilitate developing safer and more effective cardiovascular therapies, diagnostic and assessment tools.
			Duke University Cardiac Safety Research Consortium
			Norman Stockbridge, MD, PhD
			(301) 796-9841
			2015-10-28
			Indefinite225-16-005
			Establish opportunities for scientific and medical exchange between the FDA scientific staff and the University’s science students and academicians through collaborative research and training.
			University of Rochester
			OCS
			Eileen Parish, M.D.
			(301) 796-8522
			2015-12-14
			2020-12-14225-16-006
			To establish a mutually acceptable agreement between FDA and Cornell that will provide for collaboration on the development and delivery of training to FDA and State, Local, Tribal, and Territorial inspection personnel.
			Cornell University
			ORA
			Patricia L. Alcock
			Director, Division of Human Resource Development
			301-796-4299
			2015-12-18
			2020-12-18225-16-014
			Promote scientific capital, training, research, training, and research expertise. Information sharing in regulatory science research, training, sabbaticals, postdoctoral, recruitment opportunities, fellowships, and student internships.
			Rutgers University
			ORA
			Paula Davy
			(718) 340-7942
			Nazmul Hassan
			(718) 62-5707
			2016-01-26
			2026-01-26
			2021-04-14225-16-021
			Establishes terms for collaboration through a variety of programs, e.g., research, graduate student training, and exchange of scientists, exchange of staff, sabbaticals, post-doctoral fellowships, and student interns.
			Worcester Polytechnic Institute
			CDER
			Gerald J. Dal Pan, MD, MHS, CDER
			301-796-2380
			2016-08-25
			Indefinite225-16-023
			Promote share interests in collaborative education and research.
			Virginia Commonwealth University
			Padmaja Mummaneni, Ph.D.
			301-796-2027
			2016-08-16
			2027-11-08
			2022-11-08225-16-030
			To facilitate existing and new mutually agreed upon programs and activities to promote shared interests, which can be pursued through a variety of programs including collaborative education and research.
			The University of Alabama’s School of Medicine, Department of Neurology
			CDER
			Padmaja Mummaneni, Ph.D.
			10902 New Hampshire Avenue, White Oak Building 51
			Silver Spring, MD
			(301) 796-2027
			2016-12-06
			2021-12-06225-17-002
			Shared interests in promoting scientific progress through exchange of scientific capital in Clinical Pharmacology Training and Research Programs.  Replaced MOU 225-11-0006.
			University of California San Francisco
			CDER
			Padmaja Mummaneni,
			301-796-2027
			2016-10-9
			2021-10-08225-17-010
			This MOU establishes the terms for collaboration between FDA and HCV-TARGET to promote shared interests, which can be pursued through a variety of programs including collaborative
			research.
			HCV-TARGET, the University of Florida, and the University of North Carolina at Chapel Hill
			CDER
			Poonam Mishra, M.D., MPH
			Division Director (Safety)
			Division of Antiviral Products
			Office of New Drugs
			2017-02-16
			2020-02-16225-17-017
			FDA and GUMC share interests In promoting scientific progress through the exchange of scientific capital in the diverse disciplines that directly and Indirectly affect human and animal health and medicine.
			Georgetown University Medical Center
			Khaled Bouri, Ph.D.
			Office of Regulatory Science and Innovation, Office of the Chief Scientist
			301-796-8476
			2017-06-09
			2022-06-09225-17-024
			To facilitate existing and new mutually agreed upon programs and activities and establish the terms for collaboration to promote shared interests, which can be pursued through a variety of programs including collaborative education and research.
			University of Washington School of Pharmacy
			CDER
			Padmaja Mummaneni, PhD
			(301) 796-2027
			2017-09-26
			2022-09-26-225-17-026
			Promote scientific progress through exchange of scientific capital
			to enhance the assessment of safety and efficacy of FDA-regulated products through joint educational and training fellowship programs.
			Duke University
			CDER
			Padmaja Mummaneni, PhD
			301-796-2027
			2017-08-03-
			2022-08-02225-17-032
			This MOU establishes terms for collaboration to promote shared interests, which may be pursued through a variety of programs including collaborative education and research.
			University of Utah
			CDER
			Padmaja Mummaneni
			10903 New Hampshire Avenue
			FDA White Oak Building 51, Room 2164
			Silver Spring, MD 20993-0002
			Telephone Number: 301-796-2027
			2017-10-18
			2022-10-18225-17-033
			This MOU establishes the terms for collaboration to promote shared interests, which can be pursued through a variety of programs including collaborative education and research.
			University of North Carolina at Chapel Hill
			CDER
			Scott Goldie, Ph.D.
			10903 New Hampshire Avenue
			Building 21 Room 3557
			Silver Spring, MD 20993
			(301) 796-2055
			2017-09-14
			Indefinite225-17-034
			The collaborative framework this MOU provides will facilitate existing and new mutually agreed upon programs and activities and establishes the terms for collaboration to promote shared interests, which can be pursued through a variety of programs including collaborative education and research.
			Stanford University School of Medicine, Department of Bioengineering
			CDER
			Padmaja Mummaneni, PhD
			10903 New  Hampshire Avenue White Oak Building 51, Room 2164
			Silver Spring, MD 20993-0002
			(301) 796-2027
			2017-10-06
			2022-10-06225-17-035
			The parties want to collaborate on biomedical engineering projects of importance to the regulatory science priorities at CDRH.
			Zhang Bioengineering Laboratory, Clemson University
			CDRH
			Edward Margerrison, Ph.D., Director
			Office of Science and Engineering Laboratories
			Edward.Margerrison@fda.hhs.gov
			2017-09-15
			2022-09-15225-17-036
			This MOU and the collaborative framework it provides will facilitate existing and new mutually agreed upon programs and activities, consortia and consensus development between the parties and establishes the terms for collaboration to promote shared interests.
			Rutgers School of Health Professions
			CDER
			Padmaja Mummaneni, Ph.D.
			Consumer Safety Officer
			10903 New Hampshire Avenue White Oak Building 51,
			Room 2164
			Silver Spring, MD 20993
			(301) 796-2027
			2017-10-16
			2027-10-16
			2023-05-19225-17-037
			This MOU establishes the terms for collaboration to promote FDA and University of Pittsburgh’s shared interests, which can be pursued through a variety of programs.
			University of Pittsburgh
			CDER
			Padmaja Mummaneni, PhD
			(301) 796-2027
			2018-01-18
			2028-01-18
			2023-05-15225-18-001
			This MOU establishes the terms for collaboration to promote shared interests, which can be pursued through a variety of programs including collaborative education and research.
			Vanderbilt University Medical Center (VUMC)
			CDER
			Scott N. Goldie, Ph.D.
			Special Assistant for the Office of Biostatistics
			10903 New Hampshire Avenue,
			Building 21 Room 3577
			Silver Spring, MD 20993
			2017-10-30
			Indefinite225-18-004
			Establishes terms of collaboration between FDA and UMBC to support collaboration on specific projects related to biotechnology process validation, but can serve as a basis for future collaboration in other areas.
			University of Maryland, Baltimore County
			CDER
			Dr. Kurt Brorson
			(301) 796-2193
			2003-07-25
			Indefinite225-18-013
			Establishes a framework for this collaboration to enhance mutual cybersecurity and technology related interactions in education and research.
			Montgomery College
			Office of the Chief Information Officer
			Craig Taylor
			301-796-8696
			2018-03-28
			Indefinite225-18-015
			Promote shared interests in various science-based academic initiatives, fellowships, internships, sabbaticals, research and scientific education.
			Yale University
			Office of Minority Health
			CAPT Richardae Araojo
			301-796-1152
			2018-03-28
			Indefinite225-18-016
			Shared interests in promoting scientific progress through exchange of scientific capital in public health, epidemiology and research.
			State University of New York at Buffalo
			Office of Minority Health/OC
			Yeruk (Lily) Mulugeta
			301-796-3162
			2018-05-14
			2023-05-13225-18-021
			Promotes scientific progress through exchange of scientific capital in clinical pharmacy and pharmacology training, research programs, clinical research in pharmacotherapy, biopharmaceutics, clinical pharmacology and translational science.
			University of Georgia
			CDER
			2018-08-28
			2028-08-24
			2023-10-03225-18-029
			Collaborate on biomedical engineering projects of importance to the regulatory science priorities at CDRH. The parties have an interest in better understanding the bioengineering performance of many regulated medical and surgical devices.
			University of Kentucky
			CDRH
			Edward Margerrison, Ph.D.
			2018-09-18
			2023-09-18225-19-003
			The purpose of MOU 225-19-003 is to establish a framework for collaborative educational, research and training opportunities.  The joint efforts will be undertaken to develop collaborative research and training programs as permitted under appropriate statutory authority.
			Massachusetts Institute of Technology
			OC
			Sean Khozin, MD, MPH
			2019-01-30
			2024-01-30225-20-015
			The Food and Drug Administration’s (FDA) Oncology Center of Excellence (OCE), the American Association for Cancer Research (AACR), Oncology Nursing Society (ONS) and Hematology/Oncology Pharmacy Association (HOPA) agree to collaborate in Project Livin’ Label, a new educational initiative aimed at increasing awareness of recent FDA oncology drug approvals and understanding of the associated drug product label. The FDA, AACR, ONS and HOPA share interests in promoting scientific progress through exchange of scientific capital in oncology education, collaborative learning, and research. All institutions foresee benefits from collaborating in this new educational initiative focused on regulatory policy. This Memorandum of Understanding (MOU) establishes the terms for the collaboration for Project Livin’ Label and provides a basis for other related efforts to promote these shared, mutual interests in collaborative education and learning.
			American Association for Cancer Research (AACR), Oncology Nursing Society (ONS) and Hematology/Oncology Pharmacy Association (HOPA)
			Oncology Center of Excellence
			Laura B. Wisch
			Program Manager for Education
			10903 New Hampshire Ave, WO 22/2135
			Silver Spring, MD 20993Laura.Wisch@fda.hhs.gov
			301-538-6580
			2022-05-03
			2027-05-03
Sub-Topic Paragraphs
          Other CategoriesDomestic MOUs
            Agreements between FDA and other domestic government entities, including federal, state, and local agencies.Non-Profit and Other MOUs
            Agreements between FDA and other organizations, including non-profits.

                                                                                  Content current as of:
      08/07/2023Academic MOUs
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop